Background--The exact mechanism of stem cell therapy in augmenting the function of ischemic cardiomyopathy is unclear. In this study, we hypothesized that increased viability of the peri-infarct region (PIR) produces restorative benefits after stem cell engraftment. A novel multimodality imaging approach simultaneously assessed myocardial viability (manganese-enhanced magnetic resonance imaging [MEMRI]), myocardial scar (delayed gadolinium enhancement MRI), and transplanted stem cell engraftment (positron emission tomography reporter gene) in the injured porcine hearts.
heterogeneity in this vulnerable, yet salvageable, border zone has been shown to correlate with ventricular arrhythmias in patients. 2 Studies have demonstrated that the restoration of PIR viability and function improves electrical stability and outcomes in patients with ischemic cardiomyopathy. Regenerative therapies have demonstrated the ability to target the PIR to improve ventricular function and remodeling in preclinical models of heart failure [4] [5] [6] ; however, these studies have not demonstrated long-term engraftment of the transplanted stem cells or permanent restoration of the myocardium. Instead, it is believed that the transplanted stem cells undergo early lysis, which produces transient beneficial effects from the release of cytokines rather than cell engraftment. [7] [8] [9] [10] [11] To achieve sustained myocardial restoration, it may be necessary to achieve successful stem cell engraftment and increased PIR viability 7, 11 ; however, the absence of reliable in vivo tracking of these fundamental processes poses a major limitation to the translation of stem cell therapy.
In this study, we tested the hypothesis that our previously reported human amniotic mesenchymal stem cells (hAMSCs) from the placenta would enhance PIR viability. 12 The hAMSCs represent the epiblast of the inner cell mass of the embryo, giving rise to pluripotent extraembryonic mesodermal cells. These cells line the amniotic membrane at the fetal-maternal interface and demonstrate precardiac, immunomodulatory, and partially pluripotent properties. [12] [13] [14] Previous studies using mesenchymal stem cells showed significant improvement in cardiac ejection fraction and remodeling. 15 Consequently, we hypothesized that hAMSCs, which exhibit a favorable immunomodulatory profile for cardiac transplantation, would successfully restore cardiac function after ischemic injury. We used a unique in vivo myocardial viability imaging technology, manganese-enhanced magnetic resonance imaging (MEMRI), which allowed targeted imaging of viable cardiomyocytes through intracellular uptake of a manganese-based contrast agent by active L-type calcium channels without any prior genetic modification of the cells. 11 In our prior report, we demonstrated MEMRI's unique capability to characterize the injured myocardial tissue in a porcine ischemia-reperfusion model. 16 This differential uptake of manganese in the heterogeneous peri-infarct area denotes the injured, dead, and normal cardiomyocytes. This investigation exploits these unique properties of MEMRI to track the progressive changes in PIR viability in real time to understand the mechanism of stem cell therapy. Serial MEMRI characterized the changes in PIR viability, which exhibited an intermediate T1 signal relative to the remote region and intrainfarct region at baseline and an increased signal with cell therapy. The MEMRI signal increase correlated with the persistently positive positron emission tomography reporter gene (PET-RG) signal from the engrafted hAMSCs and subsequent restoration of regional and global function in the hAMSCtreated pigs.
Methods Stem Cell Line Derivation
Human placentas were obtained from consenting healthy donors at Stanford University Medical Center (Stanford, CA). The protocol was approved by Stanford University's institutional review board and was described previously. 12 Briefly, the amniotic membrane was separated from the chorion, washed, enzymatically digested, and filtered. The cells were designated as amniotic mesodermal cells (hAMSCs).
Transduction of hAMSCs With Herpes Simplex Virus Thymidine Kinase PET-RG
The hAMSCs were transduced with a double-fusion PET-RG using an established protocol. 9 The PET-RG contained firefly luciferase for bioluminescence and herpes simplex virus thymidine kinase (HSV-tk) for PET. HSV-tk phosphorylates the radioisotope 18 F-FHBG to retain the isotope intracellularly to be detected as living cells expressing HSV-tk ( Figure 1 ). The hAMSCs were incubated in lentivirus transduction medium (lentivirus multiplicity of infection of 10) for 24 hours and sorted by a fluorescence-activated cell sorter. Transduction was verified by green fluorescent protein fluorescence microscopy. 
Ischemia-Reperfusion Injury Procedure
Twelve Yorkshire swine (30 to 45 kg) were subjected to left anterior descending coronary ischemia-reperfusion injury for 60 minutes. 8, 17 Swine were anesthetized (isoflurane 1% to 2%), and heparinized (300 IU/kg IV). An angioplasty balloon was inflated in the mid-left anterior descending artery for 60 minutes. To prevent arrhythmia, amiodarone 75 mg IV was administered before ischemia. In 1 pig, direct-current defibrillation (360 J) was performed successfully. There was no procedural mortality. After 60 minutes of ischemia, the balloon was deflated, and reperfusion was documented angiographically. The vessel sheath was removed, and the wound was closed. The animals were weaned from mechanical ventilation and recovered.
Porcine Myocardial Injection
Stem cells (or saline solution controls) were delivered intramyocardially to 8 infarct and peri-infarct zones using the Helix Helical Infusion System, a distal helical needle, and a Morph Universal Deflectable Guide Catheter (BioCardia Inc). Validated protocols for this fluoroscopically guided cell delivery system in large animals and humans have been described [18] [19] [20] [21] (Figure 2) . Briefly, the targeted region was defined by MEMRI and delayed gadolinium enhancement magnetic resonance imaging (DEMRI), and then right and left anterior-oblique ventriculograms were obtained. Each 0.5-mL cell injection contained %10910 6 cells. Five control animals were injected with normal saline, and 7 animals were injected with hAMSCs. One day prior to either cell delivery or saline injection (control), the swine were administered daily cyclosporine A (10 mg/kg oral administration, Sandimmune formulation; Novartis Pharma AG) for the experimental duration. At cell delivery, a 1-time dose of 15 mg/kg methylprednisolone sodium succinate (Upjohn) was administered intravenously. 
Cardiac Magnetic Resonance Imaging Acquisition and Analysis
Cardiac magnetic resonance imaging (MRI) sequences for MEMRI and DEMRI were acquired and analyzed, as described previously. 5 Briefly, 3-T cardiac MRI was performed (Signa HDx 3.0T; General Electric) using an 8-channel chest coil and cardiac vector gating. The swine were anesthetized by isoflurane (1% to 2%). Following localizer images, steady-state acquisition was used (steady-state free procession: repetition time 3.8 ms; echo time minute full; flip angle 45°; slice thickness 10 mm; matrix 224 9 224; field of view 35) to obtain standard long-and short-axis cine images. MEMRI (fast gradient echo inversion recovery: repetition time 4. 
Cardiac Positron Emission TomographyComputed Tomography Acquisition
In 2 animals, 2 of 8 injection sites contained hAMSCs transduced with the HSV-tk PET-RG. Immediately following cell delivery and cardiac MRI, 40 mCi of 18 F-FHBG radioisotope were injected intravenously. After a 60-minute incubation (mean 536.5 MBq; range 370 to 777 MBq), positron emission tomography (PET) and computed tomography (CT) scans (Discovery LightSpeed Plus; GE Medical Systems) were performed in supine position, as described previously. 9 After an initial scout view (30 mAs, 120 kV), a nonenhanced 4-detector cardiac CT scan was obtained (section thickness 5 mm, table feed 38 mm/rotation, 0.8-second gantry rotation time, x-ray tube voltage 120 kV, tube current 150 mA). A 30-minute static PET scan was acquired. Transverse section reconstructions of the CT data set included section thicknesses of 5 mm with 4.25 mm spacing. PET images were reconstructed with an iterative algorithm (ordered-subset expectation maximization, 2 iterative steps, 28 subsets), with CT-based attenuation correction. The observed cardiac PET signal, normalized to 18 F-FHBG dosing and body weight, did not change significantly from day 0 to 3 weeks and 6 weeks after cell injection. No cardiac gating or respiratory motion correction was performed. A timeline of the experimental design is provided in Figure 4 .
Immunohistochemistry
Deparaffinization/rehydration procedure At room temperature, fixed, mounted sections were taken from the PIRs that were injected with hAMSCs and positive by MEMRI/PET imaging and from uninjected regions and were incubated in xylene. The sections were washed (29 each in 100% ethanol, 95% ethanol) and rinsed in distilled H 2 0.
Antigen unmasking
Slides were incubated in 10 mmol/L sodium citrate buffer (pH 6.0) and brought to boil using a microwave, then maintained at 95°C to 99°C for 7.5 minutes. Slides were cooled and rinsed (3 times in distilled H 2 0 and PBS).
Immunostaining
Slides were outlined using a PAP pen (Sigma-Aldrich, Inc), fixed in 4% paraformaldehyde for 20 minutes, and then rinsed (in distilled H20). The tissue was permeabilized with 0.1% Triton-X 100 (Sigma-Aldrich, Inc) for 30 minutes and washed in PBS for 5 minutes. The tissue was blocked using goat serum (Millipore, Inc) in 0.1% Triton-X 100 for 1 hour before washing 3 times in PBS (5 minutes 
Results hAMSC Harvest and HSV-tk PET-RG Transduction
From each human placental harvest, %80910 6 hAMSCs were generated at 1 to 2 cell passages ( Figure 5A ). To enable in vitro and in vivo colocalization, a subset of hAMSCs (20%) was transduced with a luciferase/HSV-tk PET-RG. 22 The in vitro bioluminescence signal remained strong for 6 weeks after transduction, with no reduction ( Figure 5B ). These transduced hAMSCs were used to verify cell injection sites and long-term engraftment in vivo. The hAMSCs express a unique cell surface marker profile, which includes the following subsets: (1) 
hAMSC Delivery Produces Sustained Improvements in LV Function and Remodeling
Serial cardiac MRI analyses demonstrated that hAMSCs conferred significant and sustained improvements in systolic function in the early hAMSC (acute injury) group (85AE34% increase in LV ejection fraction [LVEF] from preinjection level, n=4, P<0.05) measured on days 7 and 21 after injection ( Figure 7A and 7B, Videos S1 and S2). Conversely, the control animals, which received either normal saline (n=4) or lysed hAMSCs (n=1), exhibited no improvement in LVEF over the same 21-day period. In the late-hAMSC (chronic injury) group, functional restoration of a similar magnitude and time course to the early hAMSC group was observed (56AE18% increase from preinjection LVEF, n=3, P<0.05) ( Figure 7A ) and remained stable long term. The hAMSC-treated animals exhibited an absolute LVEF increase of 14AE6% (P<0.05) on day 21 after injection versus a control group ejection fraction change of À2AE5%. One late-hAMSC animal was monitored for an additional 3 weeks (total 6 weeks after hAMSC treatment) and maintained improved LVEF, suggesting durable augmentation of cardiac function. Figure 7 . LVEF and remodeling improvements in the hAMSC-treated hearts. hAMSC treatment led to sustained improvement in cardiac function. A, Mean percentage of LVEF increases in early and late-hAMSC hearts vs control hearts compared with post-IR, preinjection LVEF. The hAMSC-treated swine (light green) exhibited a significant LVEF increase immediately after hAMSC delivery (day 7) that was sustained for 21 days after delivery (day 28 after IR, day 21 after injection). NS-injected and lysed hAMSC controls showed no improvement in LVEF over the same time period. Late-hAMSC hearts, which received hAMSCs 28 days after IR injury, exhibited a predictable, significant, and steady rise in LVEF after cell delivery. B, Absolute LVEF changes before and after injection showed a consistent increase in the LVEF in hAMSCtreated swine and a consistent decrease in LVEF in the control group. C, LVEDV in hAMSC hearts exhibited 86% less chamber dilatation (percentage change in LVEDV) than the control group, indicating improved LV remodeling due to hAMSC delivery. D, MEMRI/DEMRI infarct size improvement in hAMSC-treated hearts, which exhibit a significantly lower MEMRI-defect volume and positive DEMRI scar volume compared with control hearts at 21 days after hAMSC therapy. E, A strong linear correlation was observed between the percentage change in LVEF and the percentage of infarct size reduction by MEMRI scar volume in the early hAMSC IR hearts (values expressed as percentage of total LV myocardium). Notably, the degree of scar reduction in late-hAMSC hearts is not as pronounced as in the early hAMSC hearts, despite similar LVEF increases. DEMRI indicates delayed gadolinium enhancement MRI; EF, ejection fraction; hAMSC, human amniotic mesenchymal stem cell; IR, ischemia-reperfusion; LV, left ventricular; LVEDV, left ventricular enddiastolic volume; MEMRI, manganese-enhanced magnetic resonance imaging; NS, normal saline.
A pathologic feature after myocardial infarction is severe LV dilatation. The hAMSC-treated hearts exhibited preserved LV end-diastolic volume, increasing only 30AE10% (P<0.05) in the early hAMSC group compared with baseline, whereas the control group LV end-diastolic volume increased 116AE37% (P<0.05) ( Figure 7C ). LV mass was not changed (hAMSC +18AE16 g, normal saline +9AE22 g; P>0.05). In the latehAMSC group, LV dilatation was also attenuated (LV enddiastolic volume increase +71AE25%, P<0.05 versus control). In summary, early and late-hAMSC groups showed significant and sustained functional and remodeling benefits compared with the control group.
hAMSC Delivery Enhances Regional Myocardial Viability and Function
The measurement of regional scar and viability was used to assess myocardial preservation. Early hAMSC animals exhibited a greater reduction in infarct size (P<0.05), measured by the postdelivery changes in DEMRI enhancement and MEMRI defect, compared with the control animals ( Figures 8A  through 8E and 7D) . Furthermore, in the early hAMSC group, the increased viability of the PIR measured by MEMRI correlated with improved LVEF ( Figure 7E ). To determine whether the hAMSCs augmented cardiac function locally or globally, the radial thickening percentage and the segmental PIR MEMRI signal from days 0 to 21 after injection were compared with the control group in the corresponding mid-to apical segments ( Figure 9 ). Radial thickening worsened in the control group, whereas it significantly improved in the hAMSC group ( Figure 9A and 9B) . When plotted against the corresponding change in the segmental MEMRI signal/noise ratio, the hAMSC group exhibited improved MEMRI signal/noise ratio with improved thickening, whereas the control group exhibited a reverse pattern ( Figure 9C ). Consequently, MEMRI signal correlated with regional myocardial restoration in the hAMSC-treated segments.
Prolonged In Vivo Signal of the Viable Engrafted hAMSCs Using Serial PET-CT
Serial cardiac PET-CT scans on days 0, 7, 21, and 38 were performed using an 18 F-FHBG radioisotope that is phosphorylated only by live, transduced cells to generate a PET signal. At each time point, an apical-septal PET signal (%25-fold higher than surrounding myocardium) was observed that colocalized with the sites of cell injections ( Figure 10A ). These hyperintense foci persisted throughout the duration of the study, and the specificity of the PET-RG signaling mechanism confirmed engraftment of the transplanted cells ( Figure 10C and 10D) . 9 When plotted according to the American Heart Association 16-segment model, the PET signal intensities from each myocardial segment showed a significant linear correlation with PIR MEMRI signal intensity (P<0.05) ( Figure 10E and 10F ). These persistent in vivo PET-RG foci suggest that hAMSCs survived in vivo for at least 6 weeks after injection in this swine ischemia-reperfusion model. More important, the engraftment of these live reporter gene-transduced hAMSCs was tracked longitudinally and provided real-time correlation of cell therapy with functional restoration.
Histopathological Evidence of Prolonged In Vivo Survival of Transplanted hAMSCs
Immunostaining from these colocalized apical-septal segments stained positive for anti-human nuclear antigen and anti-human mitochondrial antibodies 6 weeks after hAMSC delivery, confirming the engraftment of hAMSCs and their PET-RG signal at a prolonged time point ( Figure 11A through 11F). Moreover, these hAMSC clusters were negative for cardiac troponin or a-actinin staining, suggesting no differentiation to cardiac lineage ( Figure 11G and 11H). These immunohistological findings validated in vivo PET-CT detection of stem cell engraftment in a large animal myocardial injury model and confirmed the mechanistic correlation between stem cell engraftment and functional restoration.
Discussion
This study introduced an in vivo MEMRI technology that monitors regional myocardial restoration while providing mechanistic insight of cell therapy longitudinally. Real-time monitoring of the regional myocardial viability by the engrafted hAMSCs in the injured porcine myocardium was confirmed by colocalized cardiac PET-CT and immunofluorescent signals. These findings demonstrated the widespread utility of MEMRI to track the therapeutic efficacy of stem cell therapy by confirming the ability to restore injured cardiomyocytes in the peri-infarct myocardium. 16 A major obstacle to cardiovascular stem cell therapy is the inability to monitor the engraftment of the transplanted stem cells in vivo, which has been demonstrated to correlate with improved myocardial function. Figure 10 . MEMRI and PET colocalization of the hAMSC-injected hearts. In vivo confirmation of MEMRI signal for live hAMSCs within the myocardium of a hAMSCinjected swine is shown. hAMSCs were delivered 1 week after ischemia-reperfusion injury into the peri-infarct zones of the mid-to apical infero-and anteroseptum. A, SAX MEMRI image on day 2 with a characteristic MEMRI defect in the infarct zone (blue region of interest). Note area of inferoseptum with increased signal (star). Serial MEMRI shows increasing signal intensity in inferoseptum on days 21 and 38 after cell delivery, with overall increased signal within the infarct zone. B, Absolute increase in MEMRI CNR of the infarct zone in the hAMSC-treated vs control (normal saline-injected) hearts on day 21 after hAMSC delivery. C and D, Axial PET reporter gene signals from hAMSC populations in the apical septum, confirming specific live hAMSC activity on days 21 and 38 (IVS, LV). E, SAX MEMRI images (left) from an early hAMSC animal with traced endo-and epicardial contours; corresponding polar maps (middle) of MEMRI signal from the mid-to apical slices of the LV (the regions of hAMSC injection), with yellow and tan colors indicating increasing signal intensity; polar maps (right) from corresponding PET images. Note the similar patterns between MEMRI and PET polar maps. Arrows denote the focal signal in both MEMRI and PET images. F, Significant linear correlation of MEMRI signals (y-axis, signal intensity units) and PET signals (x-axis, signal intensity units) for both early hAMSC (left plot) and late-hAMSC (right plot) hearts. CNR indicates contrast-to-noise ratio; CT, computed tomography; hAMSCs, human amniotic mesenchymal stem cells; IVS, interventricular septum; LV, left ventricle; MEMRI, manganese-enhanced magnetic resonance imaging; PET, positron emission tomography; SAX, short-axis. engrafted hAMSC clusters, whereas the PIR viability increased significantly, yielding 3 main conclusions: (1) The live hAMSCs do not differentiate into a cardiac lineage, (2) the mechanism of any functional benefit derived from cell delivery is likely paracrine, and (3) the regional functional restoration is likely due to salvage of the injured cardiomyocytes. Notably, the degree of functional restoration in both early and late-hAMSC animals was similar, suggesting that populations of at-risk or injured cardiomyocytes may exist in the PIR of both subacute and chronic ischemic cardiomyopathy, such that cell-restorative therapy may benefit both states. Finally, MEMRI as a contrast agent has been well studied in human subjects, and prior concerns about toxicity have been overcome by use of calcium supplementation. 16, 25, 26 Consequently, clinical trials of MEMRI in cell therapy are feasible today, and plans for MEMRI clinical trials are under way. This study has several limitations. First, it is not clear to what extent MEMRI alone can distinguish healthy from injured cells. Currently, the overlap region between MEMRI and DEMRI is delineated to identify the PIR, which contains the injured cells. 16, 25, 26 Although the MEMRI signal was detectable with a significantly higher contrast/noise ratio within the injured myocardium, more investigation is required to delineate the resolution with which MEMRI can assess PIR viability. Second, quantification of the MEMRI signal is not always a discrete region but rather can be more diffuse, particularly on serial imaging. T1 mapping of the MEMRI signal may elucidate these diffuse processes. Third, the degree of myocardial salvage, regeneration, or stem cell engraftment cannot always be distinguished clearly. Recently, a group used diffusion tensor tractography in a mouse model and found that transplanted bone marrow mononuclear cells largely failed to generate new myofiber tracts required for engraftment. 27 Similarly, in this study, no evidence of cardiac differentiation was observed by immunostaining; however, a threshold value in the change in MEMRI signal to differentiate salvage versus regeneration may be possible in future studies by correlating with the histological or other measures of cardiac phenotype of engrafted stem cells. Finally, MEMRI is equally feasible at 1.5-T field strength and may require direct comparison to 3 T. In summary, this study demonstrates that stem cellmediated functional restoration is associated with a sustained improvement in PIR viability and correlates closely with stem cell engraftment. MEMRI enables direct longitudinal assessment of PIR viability and represents a novel and robust method of imaging the therapeutic efficacy of transplanted stem cells in vivo.
